AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05534984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule
Description: Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Study NCT05534984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days
Study NCT05534984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule (Open Label)
Description: * Participants weighing 4 to \<6kg and >7 days old - Tecovirimat 50mg every 12 hours for 14 days~* Participants weighing 2.5 to \<4kg and >7 days to \<4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~* Participants weighing 4 to \<6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~* Participants weighing 2.5 to \<4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Study NCT05972837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surface electrical stimulation (SES)
Description: Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
Study NCT05972837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (SES)
Description: Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
Study NCT05972837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote medical support
Description: The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
Study NCT05475015 — intervention group
Intervention type: DEVICE
Intervention: 3D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
Study NCT05475015 — intervention group
Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
Study NCT05672459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
Description: Given by IV (vein)
Study NCT05672459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)
Study NCT05672459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT05672459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Given by IV (vein)
Study NCT05322226 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Addiction follow-up before and after liver transplantation
Description: Addiction consult and follow-up
Study NCT06075121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
Study NCT06453681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bilateral PECS
Description: ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
Study NCT06453681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
Study NCT04494451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit C
Description: vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
Study NCT04494451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical Treatment
Description: iv antibiotics alone
Study NCT04494451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical Treatment
Description: iv antibiotics alone
Study NCT05594290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab i.v. 500 mg day 1
Study NCT05594290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
Study NCT05594290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/sqm iv. day 1, 2, 3
Study NCT05591053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivSight
Description: Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
Study NCT04851158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection
Description: Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants.
Study NCT04851158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection
Description: Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants.
Study NCT05863572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care health worker training
Description: Training primary care workers to detect and treat psychosis.
Study NCT05863572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care health worker training
Description: Training primary care workers to detect and treat psychosis.
Study NCT05863572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Workers Training
Description: training community health workers in detection and referral
Study NCT05863572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Workers Training
Description: training community health workers in detection and referral
Study NCT05863572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits
Description: home visits conducted by people with lived experience of psychosis
Study NCT05003492 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy plus Standard therapy
Description: Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days
Study NCT05003492 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.
Study NCT05003492 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Infected patients will receive the standard therapy for COVID-19 for 14 days
Study NCT04246164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS combined with CT
Description: HD-tDCS treatments will be administered during a cognitive training session.
Study NCT04246164 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham HD-tDCS combined with CT
Description: sham-HD-tDCS treatments will be administered during a cognitive training session.
Study NCT05509049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision nudging
Description: Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
Study NCT05509049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care communication (e.g., personalized letters and patient portal notices)
Study NCT05926440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Description: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Study NCT05926440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Description: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Study NCT05814588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads).
Study NCT05814588 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anodal TDCS
Description: RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads).
Study NCT05814588 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Anodal TDCS
Description: rehacom cognitive therapy will be provided to this group participants
Study NCT06779071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPNP-001
Description: Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.
Study NCT06779071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conjuran
Description: Description: Conjuran 2ml per injection, once a week for 5 injections.
Study NCT05820399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Guayusa Extract
Description: Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
Study NCT05820399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
Study NCT05851573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: an SLP-administered 5-week treatment focused on psychological well-being
Study NCT05701358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiology-guided NCL PCI
Description: For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
Study NCT05701358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography-guided NCL PCI
Description: PCI will be performed as per local practice
Study NCT05352841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary sample analysis
Description: The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
Study NCT06345469 — intervention group
Intervention type: OTHER
Intervention: Patient blood management (PBM)
Description: PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.
Study NCT06345469 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allogeneic transfusion
Description: transfusion of donor red cells
Study NCT06066502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision ventilation
Description: The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.
Study NCT06066502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided usual care ventilation
Description: The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
Study NCT05109572 — intervention group
Intervention type: OTHER
Intervention: Hospitalized
Description: It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.
Study NCT05109572 — intervention group
Intervention type: OTHER
Intervention: Non-hospitalized with emergency care
Description: It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
Study NCT05682833 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: Subgingival ultrasonic debridement + manual root planning
Study NCT05682833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Subgingival ultrasonic debridement + manual root planning
Study NCT04710875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Na-lactate
Description: intravenous
Study NCT04710875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Intravenous
Study NCT04770506 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT04526600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fidget ball
Description: Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
Study NCT05227118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
Study NCT05227118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 matching placebo administered orally QD
Study NCT05109572 — intervention group
Intervention type: OTHER
Intervention: Non-hospitalized and non-emergency care
Description: Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always.
Study NCT05391997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Cervical and Shoulder Retraction exercises
Description: 11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
Study NCT05391997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Extension Traction exercises
Description: 11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
Study NCT04875442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memowave emitting sounds
Description: Memowave is worn during one night and emits sounds to increase slow brain waves
Study NCT04875442 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Memowave not emitting sounds
Description: Memowave is worn during one night and doesn't emit sounds
Study NCT06508294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 week artificial intelligence based posture exercises
Description: 8 week artificial intelligence based posture exercises
Study NCT06186297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry extract
Description: polyphenol PAC-1
Study NCT06186297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract
Description: polyphenol PAC-1